Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

657.90INR
10:43am IST
Change (% chg)

Rs9.60 (+1.48%)
Prev Close
Rs648.30
Open
Rs659.00
Day's High
Rs662.00
Day's Low
Rs654.15
Volume
644,574
Avg. Vol
1,930,180
52-wk High
Rs752.85
52-wk Low
Rs545.65

CIPL.NS

Chart for CIPL.NS

About

Cipla Limited is a pharmaceutical company. The Company's business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company offers APIs, formulations and veterinary products. As of March 31, 2015, the Company offered its services across five continents across the world. It offers... (more)

Overall

Beta: 0.51
Market Cap(Mil.): Rs532,578.88
Shares Outstanding(Mil.): 803.10
Dividend: 2.00
Yield (%): 0.30

Financials

  CIPL.NS Industry Sector
P/E (TTM): 34.80 35.51 35.63
EPS (TTM): 19.05 -- --
ROI: -- 15.46 14.92
ROE: -- 16.02 15.77
Search Stocks

Lannett to buy UCB unit to boost specialty generic drugs portfolio

- Lannett Co Inc said it would buy Kremers Urban Pharmaceuticals Inc, a U.S. unit of Belgian drugmaker UCB SA , for $1.23 billion to expand its specialty generic drugs portfolio.

4:11am IST

BUZZ-India's Cipla gains; HSBC adds to EM model portfolio

Aug 19 - ** Cipla's gains 2.3 pct after HSBC adds the stock to EM model portfolio in place of Saudi International Petrochemical

19 Aug 2015

BUZZ-Muted guidance may weigh on India's Cipla despite strong April-June

** Cipla's April-June earnings beat estimates led by gains from supplies of generic Nexium to Teva

17 Aug 2015

Sensex extends gains for second session

MUMBAI - The BSE Sensex and Nifty rose on Thursday, posting their second consecutive session of gains, backed by strong earnings of Bank of Baroda and Dr Reddy's Laboratories while continued optimism over the proposed national tax bill also helped.

30 Jul 2015

BUZZ-India's Cipla gains for second day; partner Sandoz gets approval for key generic

** Partner Sandoz got U.S. FDA approval for 180 days sole exclusivity for generic version of Pulmicort respule used in treatment of Asthma on July 28: Sandoz's website shows

30 Jul 2015

MEDIA-Samina Vaziralli to take India's Cipla legacy forward - Economic Times

- Note: Reuters has not verified this story and does not vouch for its accuracy

15 Jul 2015

INTERVIEW-India's Cipla expects to double respiratory drug sales by 2020

MUMBAI, June 17 - Indian generic drugmaker Cipla expects sales from its respiratory portfolio to more than double by 2020 and remains on track to launch its potentially lucrative inhaler in Britain, its chief executive said.

17 Jun 2015

India's Cipla expects to double respiratory drug sales by 2020

MUMBAI - Indian generic drugmaker Cipla expects sales from its respiratory portfolio to more than double by 2020 and remains on track to launch its potentially lucrative inhaler in Britain, its chief executive said.

17 Jun 2015

Interview - Cipla expects to double respiratory drug sales by 2020

MUMBAI - Generic drugmaker Cipla expects sales from its respiratory portfolio to more than double by 2020 and remains on track to launch its potentially lucrative inhaler in Britain, its chief executive said.

17 Jun 2015

INTERVIEW-India's Cipla expects to double respiratory drug sales by 2020

* Says plans to enter Latin America, Eastern Europe (Adds detail, fresh CEO comments)

17 Jun 2015

Earnings vs. Estimates

Search Stocks